<DOC>
	<DOCNO>NCT00725933</DOCNO>
	<brief_summary>Safety Tolerability BIIB028</brief_summary>
	<brief_title>Administration BIIB028 Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( PHI ) accordance national local subject privacy regulation . Age great equal 18 year time inform consent . Subjects histological cytological confirm solid tumor fail standard therapy standard therapy available . Anticipated survival least 3 month opinion Investigator . ECOG performance status less equal 2 . Lab value consistent adequate renal hepatic bone marrow function . Must utilize effective contraception . Pregnant ( positive pregnancy test ) nursing woman Prior treatment Hsp90 inhibitor time . Prior antitumor therapy include prior experimental agent , approve antitumor small molecule biologics , radiotherapy 28 day &lt; 3 half life ( whichever longer ) . In addition , prior enrollment , asociated toxicity must resolve eligibility level . Concurrent severe uncontrolled medical disease ( i.e , diabetes , hypertension , coronary artery disease , congestive heart failure ) , opinion Investigator and/ Sponsor could compromise assessment safety . Use anticoagulant , except low dose warfarin . History seizure , previous significant head trauma ( e.g. , associated loss consciousness 5 minute ) , abrupt discontinuation benzodiazepine , use potentially epileptogenic medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>